Close Menu

NEW YORK – Becton Dickinson reported an 11 percent year-over-year decrease in its fiscal third quarter revenues on Thursday due to impacts of the ongoing COVID-19 pandemic.

For the three months ended June 30, the medical technology company posted $3.86 billion in revenues, down from $4.35 billion in the year-ago quarter and below the average analyst estimates of $3.94 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.